{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:03:32Z","timestamp":1748581412227},"reference-count":15,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["YAKUGAKU ZASSHI"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1248\/yakushi.20-00106","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T22:23:30Z","timestamp":1609453410000},"page":"125-133","source":"Crossref","is-referenced-by-count":2,"title":["Safe Handling Method for Splitting Azathioprine Tablets"],"prefix":"10.1248","volume":"141","author":[{"given":"Manahito","family":"Aoki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University"},{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shibazaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University"},{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magoichi","family":"Sako","sequence":"additional","affiliation":[{"name":"Ohara Pharmaceutical Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University"},{"name":"Department of Pharmacy, Kitasato University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) National Institute for Occupationl Safety and Health (NIOSH), U.S. Department of Health and Human Services. \u201cNIOSH Alert; Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings.\u201d 2004: \u3008http:\/\/www.cdc.gov\/niosh\/docs\/2004-165\/pdfs\/2004-165.pdf\u3009, cited 20 January, 2020."},{"key":"2","unstructured":"2) USP\u3008800\u3009Hazardous drugs-handling in healthcare settings, \u201cThe United States Pharmacopeia,\u201d United States Pharmacopeial Convention, Maryland, 2016."},{"key":"3","unstructured":"3) Japanese Society of Cancer Nursing (JSCN), Japanese Society of Medical Oncology (JSMO), Japanese Society of Pharmaceutical Oncology (JASPO), \u201cJSCN\/JSMO\/JASPO Joint Guidelines for Safe Handling of Cancer Chemotherapy Drugs,\u201d Kanehara Co. Ltd., Tokyo, 2015, pp. 1-99."},{"key":"4","unstructured":"4) Japanese Society of Cancer Nursing (JSCN), Japanese Society of Medical Oncology (JSMO), Japanese Society of Pharmaceutical Oncology (JASPO), \u201cJSCN\/JSMO\/JASPO Joint Guidelines for Safe Handling of Cancer Chemotherapy Drugs,\u201d Kanehara Co. Ltd., Tokyo, 2019, pp. 1-153."},{"key":"5","unstructured":"5) Yamamoto Y., Sakurai M., Watanabe N., Osada T., Toda Y., Yamamura K., Taniguchi T., Sako M., <i>J. Jpn. Soc. Pharmaceut. Oncol.<\/i>, <b>11<\/b>, 7-12 (2019)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Aoki M., Hamasaki Y., Naya M., Shishikura H., Kato M., Shibuya K., Aoyagi M., Otori K., <i>Biol. Pharm. Bull.<\/i>, <b>42<\/b>, 1823-1829 (2019).","DOI":"10.1248\/bpb.b19-00343"},{"key":"7","unstructured":"7) Aoki M., Tone N., Kanazawa A., Mitsuki Y., Yoshida R., Shibuya K., Kubota R., Sako M., Komiyama T., <i>J. Jpn. Soc. Hosp. Pharm.<\/i>, <b>52<\/b>, 287-291 (2016)."},{"key":"8","unstructured":"8) Aoki M., Kubota S., Konno Y., Owada M., Oda S., Yokota N., Shibazaki A., Shibuya K., Otori K., <i>J. Jpn. Soc. Hosp. Pharm.<\/i>, <b>55<\/b>, 273-278 (2019)."},{"key":"9","unstructured":"9) International Agency for Research on Cancer (IARC), World Health Organization, \u201cAgents classified by the IARC Monographs, Volumes 1-125.\u201d: \u3008https:\/\/monographs.iarc.fr\/list-of-classifications\u3009, cited 20 January, 2020."},{"key":"10","unstructured":"10) National Institute for Occupationl Safety and Health (NIOSH), U.S. Department of Health and Human Services. \u201cNIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016.\u201d: \u3008https:\/\/www.cdc.gov\/niosh\/docs\/2016-161\/pdfs\/2016-161.pdf?id=10.26616\/NIOSHPUB2016161\u3009, cited 20 January, 2020."},{"key":"11","unstructured":"11) Interview form of Imuran<sup>\u00ae<\/sup> Tablets 50 mg, Aspen Japan K. K., 2019: \u3008https:\/\/www.info.pmda.go.jp\/go\/interview\/X\/112268_3999005F1059_X_005_1F.pdf\u3009, cited 26 August, 2020."},{"key":"12","unstructured":"12) Interview form of AZANIN<sup>\u00ae<\/sup> Tablets 50 mg, Mitsubishi Tanabe Pharma Corporation, 2019: \u3008https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/400315_3999005F1040_1_100_1F.pdf\u3009, cited 26 August, 2020."},{"key":"13","unstructured":"13) TACROLIMUS TABLETS 0.5 mg\/1 mg\/1.5 mg\/3 mg \u201cTOWA\u201d, Product information: \u3008https:\/\/med.towayakuhin.co.jp\/medical\/property\/z_tacrolimus.html\u3009, cited 27 April, 2020."},{"key":"14","unstructured":"14) Japan Pharmaceutical Association, \u201cThe Japanese Guidelines for Dispensation,\u201d 14th ed., Yakuji Nippo Ltd., Tokyo, 2018, pp. 1-511."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Fujita Y., Hori S., Satoh H., Miki A., Sawada Y., <i>Jpn. J. Pharm. Health Care Sci.<\/i>, <b>39<\/b>, 741-749 (2013).","DOI":"10.5649\/jjphcs.39.741"}],"container-title":["YAKUGAKU ZASSHI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/141\/1\/141_20-00106\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T03:27:13Z","timestamp":1609558033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/141\/1\/141_20-00106\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/yakushi.20-00106","relation":{},"ISSN":["0031-6903","1347-5231"],"issn-type":[{"value":"0031-6903","type":"print"},{"value":"1347-5231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}